AstraZeneca: Mispriced Growth Following The Oncology Segment Success
Summarize this article with:
Aleksandr Molodets1 FollowerFollow5ShareSavePlay(25min)CommentsSummaryAstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution.AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth peers despite comparable operating leverage.DCF suggests limited upside under conservative assumptions, but peer-based multiples indicate substantial appreciation potential, supporting a GARP investment case.Valuation bands range from $79.13 (DCF) to $112.30 (peer rerating), with credible upside and disciplined risk management.Editor's note: Seeking Alpha is proud to welcome Aleksandr Molodets as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. This article was written byAleksandr Molodets1 FollowerFollowHi, I’m Alex! I focus on European financials and high-tech industries (mainly fintech, pharma, and medtech). My background goes from investor relations for tech startups, through mutual fund strategy divisions in Germany, to quantitative risk and derivatives analytics. I hold a Master in Management (Data & Business Analytics) from the Frankfurt School of Finance & Management and I’m currently working toward the CFA and FRM. My personal investing approach: I invest mainly long, with derivative overlays for hedging and risk control. My goal is to mix quantitative models with fundamental research, with the goal to understand the drivers behind companies and test whether their growth stories hold up in numbers. What I Write About: • Sectors: Financials, fintech, pharma, medtech • Focus: Small industry studies and equity research • Method: Select an industry, build a set of comparable firms, talk to people in the field (non-insider), map the main drivers, and weigh growth potential against valuation • Output: My view on whether a company fits into a solid long-term portfolio My goal is learning: I write on Seeking Alpha to share my learning process - connecting data, markets, and practitioner insights. I’m not trying to predict markets, but to understand them better and help others do the same.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Short position through short-selling of the stock, or purchase of put options or similar derivatives in AZN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.